|

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

RECRUITINGSponsored by iOMEDICO AG
Actively Recruiting
SponsoriOMEDICO AG
Started2023-09-27
Est. completion2033-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06043011

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years
* Confirmed diagnosis of the respective NHL
* If patient is alive: signed written informed consent

  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.

Exclusion Criteria:

* No systemic therapy for respective lymphoid malignancy.

Conditions7

CancerChronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma(DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Waldenström's Macroglobulinemia (WM)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.